About Us
Minimally invasive surgery innovative solution provider
About Edge
Headquartered in Shenzhen, China, Edge Medical is a seasoned practitioner in surgical robotics innovation. Backed by renowned investors such as HongShan, Temasek Holdings, and OrbiMed, we are driven by the mission to "Advancing Surgery, Elevating Care," delivering high-quality robotic solutions to healthcare institutions worldwide.
Edge Medical® has a interdisciplinary R&D and manufacturing team of over a decade of. With over a decade of technological accumulation and refinement, our core surgical robotic systems are industry benchmarking. Our company has established a robust and complete product portfolio, including multi-port endoscopic surgical robots, single-port endoscopic surgical robots, and bronchoscopic surgical robots.All the products are now available on the market.
In 2024, we conducted a groundbreaking transcontinental tele-surgery spanning from Rome and Bordeaux in Europe to Beijing, China, setting a new milestone in the history of human surgery.
With employees and partners spanning over25 countries, Edge Medical aims to advance surgical practices through technological innovation, accelerate the global adoption of robotic surgery, and improve patient outcomes worldwide.
Edge Medical is a Chinese company to offer multi-port, single-port, and bronchoscopic surgical robots

Extraordinary R&D Capabilities Established a comprehensive proprietary intellectual property system with core technology modules in surgical robot. Over 700 patents grants and applications globally.


Support from leading investors worldwide  —  With RMB360 million registered capital, Edge Medical has successfully attracted investors with the deepest understanding of medical technology, including Boyu, Temasek, HongShan, 3H Health, LYFE Capital, China State-Owned Enterprise Mixed Ownership Reform Fund and OrbiMed since established. Edge Medical was valued at over US$1.5 billion by the Cross-over round in December 2021.

Extraordinary R&D Capabilities  —  
As of December, 2025
12000+
Surgeries completed by Edge® Multi-Port Surgical Robot
2000+
Surgeries completed by Edge® Single-Port Surgical Robot
Our Culture
Mission
To advance surgical technology, empower surgeons and benefit patients
Vision
To equip every surgical room with surgical robot
Faith
To persistently pursuit of perfection in technologies to create the finest products
Core Competence
• Industry Benchmarking Technology Platform: Powered by seven core technology platforms for robotic system.
• National Award Winner Research collaboration honored with the National Science and Technology Progress Award (Second Class Prize).
700
Over 700+ patents grants and applications globally
Reward and Qualification
国家科技进步奖
第三届粤港澳大湾区生物科技创新企业50强
深圳市机器人协会 会员单位
深圳市医疗器械行业协会 会员单位
2019粤港澳大湾区生物科技创新企业50强 新锐企业
广东省手术机器人工程技术研究中心
国家级高新技术企业
2023年度中国医疗器械企业新锐100强
第三届粤港澳大湾区生物科技创新企业50强 先锋企业
创新型中小企业
专精特新中小企业
2024全球独角兽榜
广东省科技进步奖证书
SGS
Our History
To seize China's vast market opportunities and address unmet clinical needs, Edge Medical® has been dedicated to designing, developing, and manufacturing surgical robots since its establishment in 2017. Undertaking national key science project, the company was awarded the "Second Prize of 2023 National Science and Technology Progress Award".
2017~2019
Begin
2020~2021
Leap
2022~2023
Breakthrough
2024-2025
Lead
2017~2019
Early stage of operation with the ambition to lead the transformation of the high-end medical devices market in China
2017
05
Edge Medical was founded
2018
01
completed series Angel financing
2018
10
completed series A financing
2018
12
developed the prototype of MP1000 and completed the first animal testing
2019
10
developed the typeset products of both MP1000 and SP1000, and commenced pilot scale production
2020~2021
Strides in a competitive environment to lead the industry
2020
04
completed series A+ financing
2020
09
completed Pre-B financing
2021
01
completed series B financing with over RMB 500 million
2021
11
initiated the registrational clinical trial of SP1000 in gynecologic surgery
2021
12
completed registrational clinical trial of MP1000 in urologic surgery
completed Series Cross-over Financing with over USD 200 million, post-money valuation is over USD 1.5 billion
2022~2023
Continued pursuit of perfection and breakthrough to create the finest products
2022
04
Developed CP1000 prototype and completed the animal testing
2022
07
Completed patient enrollment for the registrational clinical trial of SP1000 in gynecologic surgery
2023
08
MP1000 received NMPA approval for all laparoscopic surgeries.
2023
11
SP1000 received NMPA approval for Gynecologic surgeries
2024-2025
High quality development, continuously leading the innovation of surgical robot solutions
2024
06
Won the National Science and Technology Progress Award for 2023
2024
07
Launched MP2000
2025
01
CP1000 received NMPA approval